Oncology and Hematology - MedEd On The Go

Episodes 1-16 of 93

Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
CME/CE Live Broadcast
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
December 02, 2024
03:00 PM - 03:45 PM ET
0.75 credits Learn more
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CE
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
1.00 credit
- David H. Ilson, MD, PhD
- Sunnie Kim, MD
1.00 credit
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
Diversity in HER2 Expression Among Gynecologic Cancers
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®
Diversity in HER2 Expression Among Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 credits 8 episodes
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
CME/CE
HER2-Targeted ADCs in Advanced NSCLC: A Case-Based Approach to Targeted Treatment for Metastatic Disease
0.50 credits
- Justin Gainor, MD
- Jacob Sands, MD
0.50 credits
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
MinuteCE®
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
1.00 program credit
- John Mascarenhas, MD
- Gabriela Hobbs, MD
1.00 program credit
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
MinuteCE®
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Managing Myelofibrosis-Associated Thrombocytopenia
Managing Myelofibrosis-Associated Thrombocytopenia
MinuteCE®
Managing Myelofibrosis-Associated Thrombocytopenia
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
Managing Myelofibrosis-Associated Anemia
Managing Myelofibrosis-Associated Anemia
MinuteCE®
Managing Myelofibrosis-Associated Anemia
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit

Prev
1
2
3
…
5
6
Next

1/6